Latest News | Projects Achievements

  • The ADVANCE Steering Committee met at Món St. Benet to define the last year project workplan and sustainability

    The ADVANCE Steering Committee met at Món St. Benet to define the last year project workplan and sustainability

    The ADVANCE project represents unique collaboration between key stakeholders in the sector, including European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA), national public health and regulatory bodies, vaccine manufacturers, SMEs, and academic institutions. ADVANCE aims to review, develop and test methods, data sources and procedures which should feed into a blueprint of an efficient and sustainable pan-European framework that can rapidly deliver robust quantitative data for the assessment of the benefits and risks of vaccines that are on the market. The framework supports health professionals, regulatory agencies, public health institutions and the general public make better …
  • The 3rd eTRANSAFE Consortium Meeting held in Barcelona on the 4th and 5th of June

    The 3rd eTRANSAFE Consortium Meeting held in Barcelona on the 4th and 5th of June

    Members of the 27 eTRANSAFE Consortium partners gathered for two days in Barcelona to review the progress of the project done in the past months. eTRANSAFE aims to develop predictive services, contributing to the safety assessment of chemical compounds. Integrative analysis of preclinical and clinical data for generation of candidate translational biomarkers is another important goal of the project. Francois Pognan (Novartis) and Carlos Díaz (Synapse) gave an overall vision and management of the project, followed by Eva Molero`s (Synapse) talk on the need to consider sustainability implications of any decision made in the project from the very start. The …
  • EPAD presented its next steps at the General Assembly Meeting held in Amsterdam

    EPAD presented its next steps at the General Assembly Meeting held in Amsterdam

    The fourth EPAD General Assembly was held on May 23rd-35th in Amsterdam under the banner “How to Assure Sustainability?”. Almost 180 representatives from 37 partner institutions and several other associated institutions gathered to discuss past achievements, challenges faced so far and the expected future outcomes. The EPAD project aims to develop an infrastructure that efficiently enables the undertaking of adaptive, multi-arm Proof of Concept studies for early and accurate decisions on the ongoing development of drug candidates for Alzheimer Disease. To ensure the success of the project, efforts within all work packages are continuously made as to accelerate the Trial …
  • Join the DRIVE network!

    Join the DRIVE network!

    The DRIVE Project aims at developing a governance model between public and private entities to enable a sustainable network of influenza vaccine effectiveness (IVE). Influenza is a major public health issue, it is thought to infect over 50 million of EU citizens. Vaccines are the cornerstone of preventing influenza, but their effectiveness can vary from year to year and across recipient groups. DRIVE will set up a platform, bringing together all stakeholders, to explore brand-specific effectiveness estimates for all influenza vaccines used in the EU each season, that will ultimately have a positive impact on European citizens public health. Starting …
  • AMYPAD diagnostic and patient management study (DMPS) enrolled its first research participant in Geneva last Friday

    AMYPAD diagnostic and patient management study (DMPS) enrolled its first research participant in Geneva last Friday

    The Amyloid imaging to prevent Alzheimer’s Disease project (AMYPAD) aims at studying the onset, dynamics, and clinical relevance of brain β-amyloid in the spectrum from normal aging towards mild cognitive impairment and dementia due to Alzheimer’s Disease (AD). AMYPAD studies the value of using PET (positron emission tomography) imaging for β-amyloid deposits, with the goal to determine the clinical added value of PET imaging in diagnosis and patient monitoring, and to develop data to establish its usefulness in clinical trials. Within the diagnostic and patient management sub-study (DMPS) of the AMYPAD project, researchers aim to determine the usefulness of early …
  • The first TransQST General Assembly meeting held in Finland

    The first TransQST General Assembly meeting held in Finland

    The TransQST project, launched in January 2017, aims to develop novel computational approaches using the best available data from the public and private domains to improve the assessment of drug candidates before undergoing clinical testing phase. TransQST work focuses on vital organs - liver, kidney, cardiovascular and gastrointestinal systems. The first TransQST General Assembly meeting took place on the 25th and 26th of April 2018 in Vihti, Finland. The focus of the two-day meeting was on the last updates from work packages as well on establishing the roadmap for the Early Review of the project that will take place on …
  • Synapse gathers the ROADMAP consortium partners for the 5th General Assembly Meeting

    Synapse gathers the ROADMAP consortium partners for the 5th General Assembly Meeting

    ROADMAP aspires to create the conditions for an open collaboration that yields consensual and efficient uses of RWE for the benefit of Alzheimer’s Disease patients and their caregivers. ROADMAP aims to deliver a series of data integration methods and tools for patient outcomes, which will provide the foundation for the future European RWE platform on AD. This year the ROADMAP general assembly was held in Barcelona during April 25th-26th. The consortium partners met to review ROADMAP achievements, and to discuss next steps. Key deliverables expected from the project are:  1) Develop recommendations on RWE appropriate AD‐related cognitive, functional, and behavioural …
  • Synapse organises the 6th iPiE Forum Meeting at the Biomedical Research Park of Barcelona

    Synapse organises the 6th iPiE Forum Meeting at the Biomedical Research Park of Barcelona

    iPiE (Intelligence-led Assessment of Pharmaceuticals in the Environment) aims to develop predictive tools that use information from toxicological studies, in silico models and existing datasets on environmental fate and effects of APIs (Active pharmaceutical ingredients), to support more intelligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for environmental risk assessment. The consortium comprises leading experts in data management and computational modelling, pharmacology, environmental chemistry, predictive (eco)toxicology and risk assessment. The 6th iPiE Forum meeting, held on April 24th-25th in Barcelona, was focused on progress to the development of guidance on how the established approaches and expert …
  • EMIF organises a public symposium “Liberating Evidence from European Health Data” within its closing meeting in Brussels

    EMIF organises a public symposium “Liberating Evidence from European Health Data” within its closing meeting in Brussels

    During the 16th – 18th of April, the closing EMIF meeting was held in Brussels. The main issues addressed during the meeting were project’s objectives and outcomes, impact, sustainability and lessons learned. The mission of the EMIF framework is to improve identification, access and assessment, and reuse of health data. The EMIF project, funded by IMI and started in January 2013, was aiming at developing a framework for evaluating, enhancing and providing access to human health data across Europe. The development of common technical and governance solutions, to improve access and use of health data, resulted in a secure online …
  • PARADIGM, a new IMI project managed by SYNAPSE centered in Patient Engagement, kicks off in Brussels, with the 1st Open Patient Engagement Forum

    PARADIGM, a new IMI project managed by SYNAPSE centered in Patient Engagement, kicks off in Brussels, with the 1st Open Patient Engagement Forum

    The PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines) project, funded by IMI-JU 2, was officially launched in Brussel on April 10th. The PARADIGM consortium is led by the European Patients’ Forum and EFPIA and gathers 34 partners comprising patient organisations, regulatory bodies, universities, non-for-profit organisations, SMEs, trade associations and pharmaceutical companies. PARADIGM’s mission is to provide a unique framework that enables sustainable patient engagement and demonstrates the ‘return on the engagement’ for all players. PARADIGM will build on existing tools to integrate the needs, perspectives and expectations of all actors involved and will provide a sustainable …
  • SYNAPSE attended the first Observational Health Data Sciences and Informatics (OHDSI) Symposium in Rotterdam

    SYNAPSE attended the first Observational Health Data Sciences and Informatics (OHDSI) Symposium in Rotterdam

    The first European OHDSI Symposium called "Bridging Europe” was held in Rotterdam on the 23rd and 24th of March. The Observational Health Data Sciences and Informatics (OHDSI) program is a multi-stakeholder, interdisciplinary collaborative initiative to leverage the value of health data through large-scale analytics, and it has established a global network of researchers and observational open-source health databases. OHDSI Europe is led by the Erasmus University Medical Center in Rotterdam. Peter Rijnbeek (Erasmus MC), welcomed over 200 international participants that were engaged in different sessions and tutorials. During the Symposium, several posters were presented, some of them stemming from the EMIF …
  • eTRANSAFE was presented at the PhUSE Computational Sciences Symposium in March 2018

    eTRANSAFE was presented at the PhUSE Computational Sciences Symposium in March 2018

    The Computational Sciences Symposium (CSS) celebrated its 7th annual event in Silver Spring, Maryland (US). The event brings together Academia, Regulators, Industry, and technology providers to address computational science needs in support of regulatory review in order to bring safe and effective products. CSS has established itself as the premier collaboration within the clinical trial environment, including the engagement of regulatory agencies FDA, EMA and PMDA. “eTRANSAFE, a New Player in Translational Safety Assessment” poster, written by William Drewe (Lhasa Limited), Thomas Steger-Hartmann (Bayer AG), and Montserrat Cases (Synapse) was presented at the meeting by Wiliam Drewe on behalf of …
  • Brain Awareness Week, 12th – 18th March

    Brain Awareness Week, 12th – 18th March

      The Brain Awareness Campaign is officially celebrated during this week, and we would like to use it as an opportunity to bring attention to brain science and advocate for science funding. Synapse is greatly involved in some of the most ambitious European brain research initiatives, especially those conducting research on Alzheimer’s disease. Currently, Synapse is a part of four European initiatives for Alzheimer’s disease: EPAD, AMYPAD, ROADMAP and EMIF, all funded under the auspices of the IMI-JU. EPAD (The European Prevention of Alzheimer’s Dementia) aims to create a novel environment for testing numerous interventions targeted at the prevention of …
  • Carlos Díaz presented the ROADMAP project at the XI Annual Conference of Biomedical Research Technology Platforms in Barcelona

    Carlos Díaz presented the ROADMAP project at the XI Annual Conference of Biomedical Research Technology Platforms in Barcelona

    On the 5th and 6th of March, Barcelona hosted XI Annual Conference of Biomedical Research Technology Platforms. Different advances in Innovative Medicines, Nanomedicine, Health Technology and Biotechnology Markets were presented. The focus was on the use of these advances and their necessary coexistence with the legal framework of clinical research and data protection. Synapse CEO, Carlos Díaz participated in a debate on how to share data in biomedical research. The session was focused on the experience acquired in the IMI Big Data for Better Outcomes (BD4BO) initiative including representatives from the ROADMAP and HARMONY (both managed by Synapse), BigData@Heart and …
  • Synapse supports the Association of Families Affected by Fetal Alcohol Syndrome (AFASAF) through its Social Programme

    Synapse supports the Association of Families Affected by Fetal Alcohol Syndrome (AFASAF) through its Social Programme

    In the frame of its Social Programme, Synapse has sponsored the AFASAF, a non-profit association of families affected by Fetal Alcohol Spectrum Disorders (FASD). Last Thursday members of AFASAF have visited Synapse’s premises to explain more about the FASD and the association’s activities. FASD is a lifelong condition relating to permanent brain damage caused by fetal alcohol exposure. The syndrome often goes undetected or misdiagnosed, or even blamed on poor parenting. Most children with FASD have significant cognitive, behavioural, and learning difficulties, including problems with attention, cause and effect reasoning, impulsivity and adaptive functioning difficulties. FASD has a great impact, …
  • Synapse hosts the 1st EU-ADR Alliance Methodological Workshop in Barcelona

    Synapse hosts the 1st EU-ADR Alliance Methodological Workshop in Barcelona

    On February 28th Synapse hosted the 1st EU-ADR Alliance Methodological Workshop in its offices in Barcelona. The workshop aimed at discussing recent methodological issues and applications in pharmacoepidemiological studies within the EU-ADR Alliance framework. The entire day was devoted to exploring the methods dealing with confounding and discuss on missing data, quality control and validation amongst others. The team had insightful and interesting discussions and shared experiences and learnt lessons, while deriving recommendations for future work. Researchers from IDIAP Jordi Gol (Spain), Erasmus Medical Center (the Netherlands), PEDIANET (Italy), the Italian Society of General Practitioners (Italy), the University of Oxford …
  • EPAD Academy Webinars 2018

    EPAD Academy Webinars 2018

    In 2017 the European Prevention of Alzheimer’s Dementia (EPAD) project launched EPAD Academy that is aiming to efficiently leverage EPAD resources to foster and develop academic research capacity and output in AD across Europe for maximum global impact. One of the main actions of the EPAD Academy is to help create the next generation of AD researchers by creating and facilitating opportunities for junior researchers’ career advancement. The EPAD Academy has established a register for the EPAD Academy Fellows, all of whom are eligible for Academy activities. “The Academy originated from a realisation that EPAD was an ideal framework for …
  • Registration for the 3rd Oxford Summer School on Real World Epidemiology is now open

    Registration for the 3rd Oxford Summer School on Real World Epidemiology is now open

    From 25th to 29th of June 2018, the Oxford Summer School on Real World Epidemiology will be held at the Lady Margaret Hall college in Oxford. The Director of the course is Prof Dr Prieto-Alhambra, Associate Professor and Co-Chair of the Big Health Data User Group, NDORMS, University of Oxford. This four-day training targets pharmacists, clinicians, and academics interested in the use of routinely collected data for research. The course will handle the topics such are: Data discovery and Characterization, Epidemiological study designs, Prediction modelling, Big data methods. Eva Molero, Synapse CEO, will speak on Project Management in Real World …
  • The second eTRANSAFE Consortium Meeting, hosted by Roche and co-organised by Synapse, held in Basel

    The second eTRANSAFE Consortium Meeting, hosted by Roche and co-organised by Synapse, held in Basel

    On the 6th and 7th of February, the eTRANSAFE Consortium partners met in Basel to discuss the progress of the first six months of the project. Key topics such as data collection, interoperability, and integration were discussed. One of the project aims is to develop predictive services, contributing to the safety assessment of chemical compounds. Integrative analysis of preclinical and clinical data for generation of candidate translational biomarkers is another important goal of the project. Overall the Consortium was impressed by the progress made in almost all activities and the good team collaboration established in the different WPs. The need to get …
  • eTOX Close out meeting held in Brussels

    eTOX Close out meeting held in Brussels

    On January 25th, the eTOX Executive Committee members François Pognan (Novartis Pharma), Ferran Sanz (FIMIM), Thomas Steger-Hartmann (BHC) and Carlos Díaz (SYNAPSE) held the close out meeting of the eTOX project at the IMI´s offices in Brussels. IMI´s Executive Director Dr Pierre Meulien also attended the meeting. The main points addressed during the meeting were project’s objectives and outcomes, impact, sustainability and lessons learned. The eTOX project stems from the very first IMI Call (it started in 2010) and was the very first IMI project that Synapse has managed. The project successfully ended in December 2016. With a budget of …

Recent Tweets

Follow Us

CONTACT DETAILS

Tel: +34 93 300 6061 | info@synapse-managers.com
Diputación 237, Ático 3ª. 08007 Barcelona (Spain)
Velázquez, 94. 1º Planta, 28006 Madrid (Spain)

Click to open a larger map

 
 

HIGHLIGHTS

EU-ADR Alliance
A federated collaborative framework for drug safety studies

Synapse Flyer
A quick overview of our Background and Services (PDF format)